Clinicopathological Characteristic and Prognostic Significance of Indonesian Triple Negative Breast Cancer

Irianiwati Widodo, Ery Kus Dwianingsih, Teguh Aryandono, Soeripto Soeripto

Abstract


BACKGROUND: Triple negative breast cancer (TNBC) is a breast cancer subtype with negative expressions of estrogen receptors (ER), progesterone receptors (PR) and Her-2 protein receptors. This subtype exhibits aggressive behavior and poor prognosis since it is unresponsive to hormonal and Her-2 targeted therapy. The identification of clinicopathological characteristics and their prognostic values will provide guidance in developing effective treatment. This study was performed to analyze the clinicopathological characteristics and prognostic significance in Indonesian TNBC.

METHODS: Forty paraffin-embedded tissues of TNBC, stage I to IIIA, dating from 2008 to 2010 in Dr. Sardjito Hospital, were enrolled. Survival follow-up was done from January 2008 to June 2013. The samples were immunostained with ER, PR and Her-2 monoclonal antibodies to determine the TNBC subtypes. The clinicopathological characteristics were statistically analyzed. The survival was analyzed using the Kaplan Meier method. The Cox proportional hazards model was used for multivariate analysis.

RESULTS: Mean age of TNBC patients was 51.42±11.72 years old, whereas the mean of tumor size was 5.4±2.92 cm. Lymph node metastasis was found in 70% of cases. Number of locally advanced samples (IIIA) was 37.5%, while moderate to high grade samples were 95%. Number of still alive patients at the end of the study was 55%. Number of patients that still alive up to the end of the study was 45.50%. Lymph node was an independent prognostic factor for survival of TNBC patients as positive status of lymph node increases the death risk to 6 times higher (p=0.02, RR=6.6). However, after being adjusted with age and stage, lymph node status was suggested as a modifier effect for the survival of TNBCs patients (RR=0.19).

CONCLUSION: Indonesian TNBC patients were mostly found already with large tumor size, lymph node metastasis, high pathological grade and relatively young age. Lymph node status serves as a modifier effect for the survival of Indonesian TNBC.

KEYWORDS: NBC, clinicopathological characteristics, prognostic significance

 


Full Text:

PDF

References


Kanapathy Pillai SK, Tay A, Nair S, Leong CO. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol. 2012; 12: 18, CrossRef.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26: 2373-8, CrossRef.

de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011; 137: 183-92, CrossRef.

Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23(Suppl 6): vi7-12, CrossRef.

Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, et al. Clinical characteristics in patients with triple negative breast cancer. Int J Breast Cancer. 2017; 2017: 1796145, CrossRef.

Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer-prognostic factors and survival. Radiol Oncol. 2011; 45: 46-52, CrossRef.

Wahba HA, El-Hadaad HA. Current approaches in treatment of triplenegative breast cancer. Cancer Biol Med. 2015; 12: 106-16, CrossRef.

Changavi AA, Shashikala A, Ramji AS. Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas. J Lab Physicians. 2015; 7: 79-83, CrossRef.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, et al. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep. 2017; 7: 44125, CrossRef.

Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016; 6: 1609-23, PMID.

Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev. 2016; 17: 47-52, CrossRef.

Widodo I, Dwianingsih EK, Triningsih E, Utoro T, Soeripto. Clinicopathological features of indonesian breast cancers with different molecular subtypes. Asian Pac J Cancer Prev. 2014; 15: 6109-13, CrossRef.

Widodo I, Dwianingsih EK, Anwar SL, Fx Ediati T, Utoro T, Aryandono T, et al. Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes. Asian Pac J Cancer Prev. 2017; 18: 1251-6, CrossRef.

Khambri D, Harahap WA. Survival outcomes for Indonesian women with locally advanced triple-negative breast cancer. The breast. 2017; 32: s66, CrossRef.

Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast. 4th ed. Lyon: IARC; 2012, article.

Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010; 6: 195-7, CrossRef.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25: 118-45, CrossRef.

Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triplenegative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010; 36: 206-15, CrossRef.

Naidoo K, Pinder SE. Immunohistochemistry for triple-negative breast cancer. Methods Mol Biol. 2016; 1406: 39-51, CrossRef.

Rahmawati Y, Setyawati Y, Widodo I, Ghozali A, Purnomosari D. Molecular subtypes of Indonesian breast carcinomas - lack of association with patient age and tumor size. Asian Pac J Cancer Prev. 2018; 19: 161-6, CrossRef.

Ahn KJ, Park J, Choi Y. Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. Radiat Oncol J. 2017; 35: 332-9, CrossRef.

Yu KD, Li JJ, Di GH, Wu J, Shen ZZ, Shao ZM. A straightforward but not piecewise relationship between age and lymph node status in Chinese breast cancer patients. PloS one. 2010; 5: e11035, CrossRef.

Fayaz MS, El-Sherify MS, El-Basmy A, Zlouf SA, Nazmy N, George T, et al. Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. Rep Pract Oncol Radiother. 2014; 19: 173-81, CrossRef.

Dogra A, Doval DC, Sardana M, Chedi SK, Mehta A. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. Asian Pac J Cancer Prev. 2014; 15: 10577-83, CrossRef.

Ishitha G, Manipadam MT, Backianathan S, Chacko RT, Abraham DT, Jacob PM. Clinicopathological study of triple negative breast cancers. J Clin Diagn Res. 2016; 10: EC05-9, CrossRef.

Zhu W, Perez EA, Hong R, Li Q, Xu B. Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: A population-based study from SEER Cancer Registries. PloS One. 2015; 10: e0128345, CrossRef.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-502, CrossRef.

Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triplenegative breast cancer in India: systematic review and metaanalysis. J Glob Oncol. 2016; 2: 412-21, CrossRef.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-34, CrossRef.

Yang D, Liu H, Zhao J. Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer. Chinese J Clin Oncol. 2008; 5: 387-90, CrossRef.

Qiu J, Xue X, Hu C, Xu H, Kou D, Li R, et al. Comparison of clinicopathological features and prognosis in triple-negative and non-triple negative breast cancer. J Cancer. 2016; 7: 167-73, CrossRef.

Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, et al. Triplenegative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017; 161: 279-87, CrossRef.

Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, et al. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PloS one. 2011; 6: e23543, CrossRef.

Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014; 15: e625-34, CrossRef.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003; 100: 8418-23, CrossRef.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-74, CrossRef.

Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110: 876-84, CrossRef.

Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, et al. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol. 2014; 2: 245-51, CrossRef.

Sun W, Li C, Liu M, Liu W, Yang C, Cai LI. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncology letters. 2016; 11: 2320-6, CrossRef.

Chen H, Ding A, Wang M, Yin C, Zhang Z. Prognostic significance of lymph node metastasis in triple negative ductal carcinoma of the breast: a retrospective cohort study. Int J Clin Exp Med. 2017; 10: 2727-36, article.

Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, et al. The lymph node ratio as an independent prognostic factor for nonmetastatic node-positive breast cancer recurrence and mortality. J BUON. 2015; 20: 737-45, PMID.

He M, Zhang JX, Jiang YZ, Chen YL, Yang HY, Tang LC, et al. The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget. 2017; 8: 44870-80, CrossRef.

Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 2018; 18: 56, CrossRef.




DOI: https://doi.org/10.18585/inabj.v11i3.831

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute